Clinical Study of Tigilanol Tiglate for Soft Tissue Sarcoma
This study is looking at how well a drug called Tigilanol Tiglate works in people with advanced or metastatic (spread to other parts of the body) soft tissue sarcoma. Tigilanol Tiglate is given directly into the tumor. Researchers want to see if it can shrink or get rid of tumors, and how it affects the overall disease. They will also check for side effects and how the body handles the drug. You might be able to join if you are 18 or older and have soft tissue sarcoma in your body wall or limbs that can be injected. The study aims to enroll 40 participants.
- Study design
- This is an open-label study, meaning both you and the study team will know which treatment you are receiving. It plans to enroll 40 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure tumor response at 3 and 6 months after the initial treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Edmund Bartlett, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Tumour Response6 months
Proportion of participants who have achieved partial or complete ablation of treated tumour(s) and/or tumour segment(s) following injection(s) with tigilanol tiglate.
- ORR as determined by RECIST3 and 6 months post initial treatment (Stage 2 only)
Objective Response Rate (ORR) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST) V1.1